Gastroenterology

Patients With RA, IBD Trust Specialists’ Biologic and Biosimilar Recommendations

February 24th 2023

By Justina Petrullo

Patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) have similar positive attitudes towards biologics and both trust their specialists’ recommendations, according to a recent survey conducted in Australia.

Report: Over 60% of Providers Plan to Only Prescribe Interchangeable Adalimumab Biosimilars

February 23rd 2023

By Skylar Jeremias

Article

In Cardinal Health’s 2023 Biosimilars Report, more than 60% of surveyed providers said they would only want to prescribe adalimumab biosimilars with interchangeability designations, suggesting the label may have a greater impact on uptake than originally expected.

Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan Launch

February 23rd 2023

By Skylar Jeremias

Article

Fresenius Kabi announced a global partnership with Formycon for an ustekinumab biosimilar; Similis Bio partners with Novel351K to co-develop 3 biosimilars; and Celltrion Healthcare launched its bevacizumab biosimilar in Japan.

Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study

February 8th 2023

By Skylar Jeremias

Article

Formycon shared positive data on its Eylea (aflibercept) biosimilar; Sandoz received a thumbs up from the European Union’s Committee for Medicinal Products for Human Use (CHMP); and Shanghai Henlius Biotech began a phase 1 study for its daratumumab biosimilar candidate.

Vizient Report Predicts Over 3% Inflation Rate for Biologics

February 7th 2023

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report examined the impact that factors, such as the COVID-19 pandemic and the US market introduction of adalimumab biosimilars, will have on drug prices and the utilization of lower-cost biologics.

US Welcomes First Adalimumab Biosimilar, Amjevita

January 31st 2023

By Skylar Jeremias

Article

Amgen’s Amjevita (adalimumab-atto) has officially entered the US market, making it the first of potentially 10 biosimilars referencing Humira to launch in 2023.

Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

January 26th 2023

By Skylar Jeremias

Article

Saudi Arabia approved an adalimumab biosimilar, a denosumab biosimilar entered the market in the Republic of Korea, and Dr. Reddy’s Laboratories announced the completion of a phase 3 study for its rituximab biosimilar.

FDA Accepts BLA for Alvotech Ustekinumab Biosimilar

January 6th 2023

By Skylar Jeremias

Article

Alvotech, an Iceland-based company, announced that the FDA accepted its biologics license application (BLA) for its proposed ustekinumab biosimilar referencing Stelara. The company said it expects the FDA’s decision in the second half of 2023.

Celltrion Submits BLA for Infliximab Biobetter

January 5th 2023

By Skylar Jeremias

Article

Celltrion Healthcare submitted a biologics license application (BLA) to the FDA for its biobetter of its infliximab biosimilar allowing for subcutaneous administration (Remsima SC).

Canada Approves High-Concentration Humira Biosimilar

January 3rd 2023

By Skylar Jeremias

Article

Health Canada has approved the high-concentration version of Samsung Bioepis and Organon’s Hadlima, a citrate-free adalimumab biosimilar referencing Humira.